TNF and rheumatoid arthritis: These days, certolizumab and golimumab are the newer, less studied anti-TNF-α antibodies most recently approved by the FDA for the treatment of RA, psoriatic arthritis, ankylosing spondylitis, Crohn's disease unresponsive to regular medications (certolizumab), and ulcerative colitis (golimumab).